Male Reproduction
16 cases on TRT initiation and formulation choice, male infertility and fertility preservation, erectile dysfunction beyond PDE5 monotherapy, Klinefelter and Kallmann syndrome, and hormonal male contraception — choose a case below to open its full multi-voice debate.
A symptomatic 52-year-old whose two morning testosterone levels land on opposite sides of the usual 300 ng/dL line — and a debate over whether the diagnosis is even settled yet.
A 34-year-old electrician with confirmed hypogonadism and a wife trying to conceive — where the standard fix for his symptoms is also the one option guaranteed to work against what he actually wants next.
A 61-year-old with confirmed hypogonadism, a genuine needle aversion, and grandchildren who visit weekly — testing which testosterone formulation actually fits a specific household, not an abstract ranking of routes.
A 68-year-old, three years past a prostatectomy for low-risk prostate cancer, with an undetectable PSA and hypogonadal symptoms he almost didn't mention — testing how far a decades-old contraindication has actually moved.
A 45-year-old on injectable testosterone whose hematocrit has climbed to 55% — and a genuine dispute over whether the standard fix, phlebotomy, is actually the safer move or a well-intentioned one the evidence doesn't yet support.
A 31-year-old with idiopathic low-count sperm and testosterone that reads low-normal, not clearly deficient — testing whether an empiric hormonal trial is defensible medicine or just a plausible-sounding habit.
A 58-year-old whose erectile dysfunction hasn't responded to sildenafil — and a debate over whether he has genuinely failed the drug, or never actually been given a fair trial of it.
A 19-year-old freshly diagnosed with Klinefelter syndrome, hypogonadal and ready to start testosterone — except starting it now may close a fertility door that is already narrowing on its own.
A 29-year-old competitive bodybuilder, four months off self-administered anabolic steroids, whose own hormone axis hasn't come back on its own — and a debate over whether to help restart it or simply wait it out.
A 55-year-old long-haul trucker with confirmed hypogonadism and a wife who has been counting the seconds between his breaths — testing whether testosterone can wait for a sleep study a safety-sensitive job makes hard to schedule.
A 26-year-old whose sexual side effects from a hair-loss medication haven't resolved five months after he stopped taking it — and a genuinely contested question of what, medically, can honestly be told to him about why.
A 71-year-old on androgen deprivation therapy who is already noticing the breast changes prophylaxis is meant to prevent — testing what's actually left to offer once the usual window for prevention has arguably passed.
A 22-year-old on the testosterone that carried him through a delayed puberty now asking to come off it — to start a much slower, less certain regimen aimed at something testosterone itself can't give him.
A 47-year-old with a year of unmonitored compounded testosterone from a direct-to-consumer clinic and an incidentally elevated hematocrit — testing what an honest re-entry into the regulated system actually looks like.
A 33-year-old testicular cancer survivor, six years past treatment and feeling fine until recently — testing whether new fatigue reflects late hormonal fallout from a cancer he thought he'd left behind, or something that still needs repeat confirmation before it's named that way.
A 36-year-old asking for a male birth control shot he saw discussed online, in a field where the most promising candidate has completed only Phase 2 and nothing is actually FDA-approved yet.